Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No deal unless USA mj laws change........tha's part of the deal.
This is not a done deal!.....Don't put all your eggs in one basket.
"We believe that any claims alleging violations of securities laws by the Company are without merit and we intend to vigorously defend our position," stated Joseph Dowling, Chief Executive Officer of CV Sciences.
The lawsuit piggy-backs on allegations made in a public "report" by Citron Research, a firm that sources indicate is run by an activist short seller. Citron issued its report on Monday, August 20(th) , after the Company's stock had risen more than 25% in the day.
Both the Citron report and the newly filed lawsuit allege, in pertinent part, that the Company violated securities laws by failing to disclose that it had received notice from the United States Patent and Trademark Office (USPTO) that its pending patent application, U.S. Patent Application No. 15/426,617 (the '617 Application), had been "finally rejected" by the USPTO. The complaint draws the conclusion that this notice from the USPTO terminated the Company's patent application, and that the Company's efforts to obtain patent protection for the inventions disclosed in the '617 Application have therefore failed.
"The conclusions in the complaint and in the 'report' by Citron Research are outright false, and demonstrate either an ignorance, a disregard, or both, of the basics of patent prosecution," stated Mr. Dowling. "A 'final rejection' in the context of patent prosecution is anything but final. It by no means indicates that the applicant has failed in its efforts to obtain an issued patent." We will continue to prosecute the '617 Application and plan to file and prosecute several more applications related to the inventions described in the '617 Application."
Mr. Dowling continued, "While the end result is not assured, both the Company and our patent counsel at Banner & Witcoff continue to have comfort that we will obtain an issued patent pursuant to the '617 Application."
CVSI responds
Did DP just buy more stock?
This could mean something important is going to happen soon.
TRTC is conducting a 15:1 reverse split
RS .... 15-1 rs is happening
Good news, not great news, good news.
https://www.theguardian.com/us-news/2018/mar/10/marijuana-jeff-sessions-prosecutors
News
............. The NuLeaf team, which has operated BPG cannabis dispensary in Berkeley, CA, has been a premier vertically integrated supplier in California for over two decades.
Thanks for the link sleepernw.
Only up listing to a major index will they do a RS
Very strong quarter!
The Edible Garden segment also reported strong growth in the second quarter
record revenues
Great point! thanks.
You make a VERY good point, thanks.
This is an important step in the right direction.
not so good,sorry.
Others were relieved that the D.E.A. had moved to allow more institutions to grow marijuana for research, but not taken it off the list of the most dangerous drugs.
I did not sell, in fact I bought more today. Read the report again please.
News is not that good. sorry.
It was a shock to most. PHOT spiked on that day.
Thanks sleepernw, great DD.
Link please?
And it seems to be working. $$$